Cargando…

Empowering the Potential of CAR-T Cell Immunotherapies by Epigenetic Reprogramming

SIMPLE SUMMARY: Epigenetic mechanisms are key players in many diseases, including cancer. Unlike genetic changes, epigenetic modifications are reversible without leaving a permanent mark on DNA. Epigenetic therapies, using epigenome-influencing techniques, aim to normalize DNA methylation patterns o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alvanou, Maria, Lysandrou, Memnon, Christophi, Panayota, Psatha, Nikoleta, Spyridonidis, Alexandros, Papadopoulou, Anastasia, Yannaki, Evangelia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10093039/ https://www.ncbi.nlm.nih.gov/pubmed/37046597 http://dx.doi.org/10.3390/cancers15071935

Ejemplares similares

Hypomethylation-induced regulatory programs in T cells unveiled by transcriptomic analyses
por: Lysandrou, Memnon, et al.
Publicado: (2023)

P1360: CLINICAL TRANSLATION OF A NOVEL, POTENT AND WELL-CHARACTERIZED INDUCED REGULATORY T-CELL PRODUCT AGAINST GRAFT VERSUS HOST DISEASE
por: Lysandrou, Memnon, et al.
Publicado: (2023)

Study protocol: Phase I/II trial of induced HLA-G(+) regulatory T cells in patients undergoing allogeneic hematopoietic cell transplantation from an HLA-matched sibling donor
por: Lysandrou, Memnon, et al.
Publicado: (2023)

“Cerberus” T Cells: A Glucocorticoid-Resistant, Multi-Pathogen Specific T Cell Product to Fight Infections in Severely Immunocompromised Patients
por: Koukoulias, Kiriakos, et al.
Publicado: (2021)

In Vivo Hematopoietic Stem Cell Genome Editing: Perspectives and Limitations
por: Psatha, Nikoletta, et al.
Publicado: (2022)

Pathogen-specific T Cells: Targeting Old Enemies and New Invaders in Transplantation and Beyond
por: Papadopoulou, Anastasia, et al.
Publicado: (2023)

Precision Editing as a Therapeutic Approach for β-Hemoglobinopathies
por: Paschoudi, Kiriaki, et al.
Publicado: (2023)

Reprogramming systemic and local immune function to empower immunotherapy against glioblastoma
por: Zhou, Songlei, et al.
Publicado: (2023)

Reinforcing the Immunocompromised Host Defense against Fungi: Progress beyond the Current State of the Art
por: Karavalakis, Georgios, et al.
Publicado: (2021)

Patient risk stratification and tailored clinical management of post‐transplant CMV‐, EBV‐, and BKV‐infections by monitoring virus‐specific T‐cell immunity
por: Papadopoulou, Anastasia, et al.
Publicado: (2021)

Intratumoral IL-12 delivery empowers CAR-T cell immunotherapy in a pre-clinical model of glioblastoma
por: Agliardi, Giulia, et al.
Publicado: (2021)

P1395: PENTAVALENT-SPECIFIC T-CELLS POST HAPLO-IDENTICAL TRANSPLANTATION FOR THE TREATMENT OF OPPORTUNISTIC INFECTIONS
por: Bousiou, Zoi, et al.
Publicado: (2023)

Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming
por: Wang, Yao, et al.
Publicado: (2021)

P1370: A NOVEL GENE THERAPY VECTOR FOR BETA-HEMOGLOBINOPATHIES WITH A SELECTIVE EXPANSION CASSETTE
por: Kirtsou, Alexandra, et al.
Publicado: (2023)

Potential solutions for manufacture of CAR T cells in cancer immunotherapy
por: Blache, Ulrich, et al.
Publicado: (2022)

Empowering therapeutic antibodies with IFN-α for cancer immunotherapy
por: Guo, Jun, et al.
Publicado: (2019)

Epigenetic Reprogramming of CD4(+) Helper T Cells as a Strategy to Improve Anticancer Immunotherapy
por: Renaude, Elodie, et al.
Publicado: (2021)

CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
por: Pan, Kevin, et al.
Publicado: (2022)

Robust SARS-COV-2-specific T-cell immune memory persists long-term in immunocompetent individuals post BNT162b2 double shot
por: Papadopoulou, Anastasia, et al.
Publicado: (2022)

miR-155 harnesses Phf19 to potentiate cancer immunotherapy through epigenetic reprogramming of CD8(+) T cell fate
por: Ji, Yun, et al.
Publicado: (2019)

Epigenetic Reprogramming and Emerging Epigenetic Therapies in CML
por: Bugler, Jane, et al.
Publicado: (2019)

Brief Report: A Differential Transcriptomic Profile of Ex Vivo Expanded Adult Human Hematopoietic Stem Cells Empowers Them for Engraftment Better than Their Surface Phenotype
por: Psatha, Nikoletta, et al.
Publicado: (2017)

Combined immunotherapy for advanced prostate cancer: Empowering the T cell army
por: Suleman, Sufyan, et al.
Publicado: (2017)

A MILI-independent piRNA biogenesis pathway empowers partial germline reprogramming
por: Vasilauskaitė, Lina, et al.
Publicado: (2017)

Disruption of the BCL11A Erythroid Enhancer Reactivates Fetal Hemoglobin in Erythroid Cells of Patients with β-Thalassemia Major
por: Psatha, Nikoletta, et al.
Publicado: (2018)

Reprogramming T cell differentiation and exhaustion in CAR-T cell therapy
por: Bulliard, Yannick, et al.
Publicado: (2023)

Epigenetic reprogramming in the mammalian germline
por: Hsu, Fei-Man, et al.
Publicado: (2015)

Age reprogramming and epigenetic rejuvenation
por: Singh, Prim B., et al.
Publicado: (2018)

Cellular reprogramming and epigenetic rejuvenation
por: Simpson, Daniel J., et al.
Publicado: (2021)

Epigenetic Trajectories of Aging and Reprogramming
por: Niimi, Peter, et al.
Publicado: (2021)

Is a third SARS‐CoV‐2 vaccine dose efficient in allogeneic haematopoietic cell transplant recipients?
por: Spyridonidis, Alexandros
Publicado: (2022)

Epigenetic reprogramming of Runx3 reinforces CD8 + T-cell function and improves the clinical response to immunotherapy
por: Liu, Zongzhi, et al.
Publicado: (2023)

CAR T cell-based immunotherapy and radiation therapy: potential, promises and risks
por: Hovhannisyan, Lusine, et al.
Publicado: (2023)

Versatile CAR T-cells for cancer immunotherapy
por: Chu, Fuliang, et al.
Publicado: (2018)

Tuning the performance of CAR T cell immunotherapies
por: Richardson, Noah H., et al.
Publicado: (2019)

Adoptive Immunotherapy beyond CAR T-Cells
por: Titov, Aleksei, et al.
Publicado: (2021)

Contextual reprogramming of CAR-T cells for treatment of HER2(+) cancers
por: Yang, Zhifen, et al.
Publicado: (2021)

Optimized antiangiogenic reprogramming of the tumor microenvironment potentiates CD40 immunotherapy
por: Kashyap, Abhishek S., et al.
Publicado: (2020)

Polypyrrole Nanoenzymes as Tumor Microenvironment Modulators to Reprogram Macrophage and Potentiate Immunotherapy
por: Zeng, Weiwei, et al.
Publicado: (2022)

Epigenetic reprogramming in the porcine germ line
por: Hyldig, Sara MW, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_f89q6m9licsl57b671r9ebt70m